Cargando…
Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices
BACKGROUND: Increasing pharmaceutical expenditure challenges the sustainability and accessibility of healthcare systems across Europe. Confidentiality restraints hinder assessment of actual prices of Orphan Medicinal Products (OMPs). Hence, we assessed the real prices of brand-name OMPs around marke...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628053/ https://www.ncbi.nlm.nih.gov/pubmed/37751107 http://dx.doi.org/10.1007/s40258-023-00832-6 |
_version_ | 1785131670472491008 |
---|---|
author | Dane, Aniek Klein Gebbink, Anne-Sophie Brugma, Jan-Dietert Degrassat-Théas, Albane Hug, Martin J. Houlind, Morten B. Paubel, P. van der Kuy, P. Hugo M. Uyl-de Groot, Carin A. |
author_facet | Dane, Aniek Klein Gebbink, Anne-Sophie Brugma, Jan-Dietert Degrassat-Théas, Albane Hug, Martin J. Houlind, Morten B. Paubel, P. van der Kuy, P. Hugo M. Uyl-de Groot, Carin A. |
author_sort | Dane, Aniek |
collection | PubMed |
description | BACKGROUND: Increasing pharmaceutical expenditure challenges the sustainability and accessibility of healthcare systems across Europe. Confidentiality restraints hinder assessment of actual prices of Orphan Medicinal Products (OMPs). Hence, we assessed the real prices of brand-name OMPs around market exclusivity expiry (MEE). OBJECTIVE: We aimed to explore developments in published list prices (LPs) and confidential hospital purchase prices (PPs) of brand-name OMPs relative to their market exclusivity status in Western European countries with similar GDPs. METHODS: We analyzed LPs and PPs of 13 selected OMPs purchased by university hospitals in Western European countries between 2000 and 2020. For confidentially reasons, proportions were used, with the Dutch LPs of the selected OMPs at the year of MEE serving as reference values. PPs included pre-purchase discounts. Rebates were not considered. RESULTS: Data were analyzed from hospitals in Denmark (DK) (n = 1), France (FR) (n = 1), Germany (DE) (n = 2), and the Netherlands (NL) (n = 1). Average LPs and PPs of included OMPs dropped gradually but limited over time, with no explicit price drop after MEE. LP levels differed more per country than PP levels: LP range before MEE was 164% (DE)–101% (FR) and after MEE was 135% (DE)–82% (FR); PP range before MEE was 150% (DE)–102% (FR) and after MEE was 107% (DE)–80% (FR). Overall differences between LPs and PPs were < 3% in all countries, except for Denmark. CONCLUSION: No evident price drops of included brand-name OMPs were observed around MEE and differences in purchase prices are modest in the selected Western European countries. Results were not subject to significance testing. More robust data are needed to strengthen negotiations with suppliers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40258-023-00832-6. |
format | Online Article Text |
id | pubmed-10628053 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-106280532023-11-08 Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices Dane, Aniek Klein Gebbink, Anne-Sophie Brugma, Jan-Dietert Degrassat-Théas, Albane Hug, Martin J. Houlind, Morten B. Paubel, P. van der Kuy, P. Hugo M. Uyl-de Groot, Carin A. Appl Health Econ Health Policy Original Research Article BACKGROUND: Increasing pharmaceutical expenditure challenges the sustainability and accessibility of healthcare systems across Europe. Confidentiality restraints hinder assessment of actual prices of Orphan Medicinal Products (OMPs). Hence, we assessed the real prices of brand-name OMPs around market exclusivity expiry (MEE). OBJECTIVE: We aimed to explore developments in published list prices (LPs) and confidential hospital purchase prices (PPs) of brand-name OMPs relative to their market exclusivity status in Western European countries with similar GDPs. METHODS: We analyzed LPs and PPs of 13 selected OMPs purchased by university hospitals in Western European countries between 2000 and 2020. For confidentially reasons, proportions were used, with the Dutch LPs of the selected OMPs at the year of MEE serving as reference values. PPs included pre-purchase discounts. Rebates were not considered. RESULTS: Data were analyzed from hospitals in Denmark (DK) (n = 1), France (FR) (n = 1), Germany (DE) (n = 2), and the Netherlands (NL) (n = 1). Average LPs and PPs of included OMPs dropped gradually but limited over time, with no explicit price drop after MEE. LP levels differed more per country than PP levels: LP range before MEE was 164% (DE)–101% (FR) and after MEE was 135% (DE)–82% (FR); PP range before MEE was 150% (DE)–102% (FR) and after MEE was 107% (DE)–80% (FR). Overall differences between LPs and PPs were < 3% in all countries, except for Denmark. CONCLUSION: No evident price drops of included brand-name OMPs were observed around MEE and differences in purchase prices are modest in the selected Western European countries. Results were not subject to significance testing. More robust data are needed to strengthen negotiations with suppliers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40258-023-00832-6. Springer International Publishing 2023-09-26 2023 /pmc/articles/PMC10628053/ /pubmed/37751107 http://dx.doi.org/10.1007/s40258-023-00832-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Article Dane, Aniek Klein Gebbink, Anne-Sophie Brugma, Jan-Dietert Degrassat-Théas, Albane Hug, Martin J. Houlind, Morten B. Paubel, P. van der Kuy, P. Hugo M. Uyl-de Groot, Carin A. Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices |
title | Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices |
title_full | Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices |
title_fullStr | Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices |
title_full_unstemmed | Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices |
title_short | Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices |
title_sort | prices of orphan drugs in four western european countries before and after market exclusivity expiry: a cross-country comparison of list prices and purchase prices |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628053/ https://www.ncbi.nlm.nih.gov/pubmed/37751107 http://dx.doi.org/10.1007/s40258-023-00832-6 |
work_keys_str_mv | AT daneaniek pricesoforphandrugsinfourwesterneuropeancountriesbeforeandaftermarketexclusivityexpiryacrosscountrycomparisonoflistpricesandpurchaseprices AT kleingebbinkannesophie pricesoforphandrugsinfourwesterneuropeancountriesbeforeandaftermarketexclusivityexpiryacrosscountrycomparisonoflistpricesandpurchaseprices AT brugmajandietert pricesoforphandrugsinfourwesterneuropeancountriesbeforeandaftermarketexclusivityexpiryacrosscountrycomparisonoflistpricesandpurchaseprices AT degrassattheasalbane pricesoforphandrugsinfourwesterneuropeancountriesbeforeandaftermarketexclusivityexpiryacrosscountrycomparisonoflistpricesandpurchaseprices AT hugmartinj pricesoforphandrugsinfourwesterneuropeancountriesbeforeandaftermarketexclusivityexpiryacrosscountrycomparisonoflistpricesandpurchaseprices AT houlindmortenb pricesoforphandrugsinfourwesterneuropeancountriesbeforeandaftermarketexclusivityexpiryacrosscountrycomparisonoflistpricesandpurchaseprices AT paubelp pricesoforphandrugsinfourwesterneuropeancountriesbeforeandaftermarketexclusivityexpiryacrosscountrycomparisonoflistpricesandpurchaseprices AT vanderkuyphugom pricesoforphandrugsinfourwesterneuropeancountriesbeforeandaftermarketexclusivityexpiryacrosscountrycomparisonoflistpricesandpurchaseprices AT uyldegrootcarina pricesoforphandrugsinfourwesterneuropeancountriesbeforeandaftermarketexclusivityexpiryacrosscountrycomparisonoflistpricesandpurchaseprices |